111 assets in Rectal Carcinoma

Therapeutic assets addressing Rectal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Sildenafil Rectal Carcinoma	University Hospital, Rouen	P3	CCC (53)
Trastuzumab Emtansine Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Vismodegib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Zanidatamab Rectal Carcinoma	Emory University	P2	CCC (53)
1.0% ip-001 for Rectal Carcinoma	Immunophotonics, Inc.	P2/3	CCC (52)
Adavosertib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Dehydroepiandrosterone Rectal Carcinoma	Ohio State University Comprehensive Cancer Center	P2	CCC (52)
ip-001 Rectal Carcinoma	Immunophotonics, Inc.	P2/3	CCC (52)
Adebrelimab Rectal Carcinoma	SCRI Development Innovations, LLC	P2	CCC (51)
Balstilimab Rectal Carcinoma	Memorial Sloan Kettering Cancer Center	P2	CCC (51)
Bmx-001 Free Base Rectal Carcinoma	University of Nebraska	P2	CCC (51)
Botensilimab Rectal Carcinoma	Memorial Sloan Kettering Cancer Center	P2	CCC (51)
Cabozantinib Rectal Carcinoma	University of Colorado, Denver	P2	CCC (51)
Catequentinib Rectal Carcinoma	Shanghai Minimally Invasive Surgery Center	P2	CCC (51)
Dcsz11 Rectal Carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (51)
Etrumadenant Rectal Carcinoma	Weill Medical College of Cornell University	P2	CCC (51)
Ivonescimab Rectal Carcinoma	Zhejiang Cancer Hospital	P2	CCC (51)
Lorigerlimab Rectal Carcinoma	M.D. Anderson Cancer Center	P2	CCC (51)
Penpulimab Rectal Carcinoma	Ruijin Hospital	P2	CCC (51)
Pimurutamab Rectal Carcinoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P2	CCC (51)
Taselisib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Tegafur Gimeracil Oteracil Potassium Rectal Carcinoma	Guangzhou University of Traditional Chinese Medicine	P2	CCC (51)
Tiragolumab Rectal Carcinoma	Hoffmann-La Roche	P2	CCC (51)
Toripalimab Rectal Carcinoma	Ruijin Hospital	P2	CCC (51)
Tucatinib Rectal Carcinoma	Memorial Sloan Kettering Cancer Center	P2	CCC (51)
Zimberelimab Rectal Carcinoma	Weill Medical College of Cornell University	P2	CCC (51)
Copanlisib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (49)
Cea-Targeted Car-T Rectal Carcinoma	Chongqing Precision Biotech Co., Ltd	P1/2	CCC (48)
Polypepi1018 Rectal Carcinoma	Mayo Clinic	P1	CC (47)
Modified Vaccinia Virus Ankara Vaccine Expressing P53 Rectal Carcinoma	City of Hope Medical Center	P1	CC (46)
[111In]In-DOTA-ANTI-CEA antibody Rectal Carcinoma	Radboud University Medical Center	P1/2	CC (43)
a2b395 Rectal Carcinoma	A2 Biotherapeutics Inc.	P1/2	CC (43)
a2b543 Rectal Carcinoma	A2 Biotherapeutics Inc.	P1/2	CC (43)
a2b694 Rectal Carcinoma	A2 Biotherapeutics Inc.	P1/2	CC (43)
Anti-Kras G12V Mtcr Pbl Rectal Carcinoma	National Cancer Institute (NCI)	P1/2	CC (43)
atp128 Rectal Carcinoma	Amal Therapeutics	P1	CC (43)
Ezabenlimab Rectal Carcinoma	Amal Therapeutics	P1	CC (43)
Fludarabine Rectal Carcinoma	National Cancer Institute (NCI)	P1/2	CC (43)
gsk4418959 Rectal Carcinoma	GlaxoSmithKline	P1/2	CC (43)
mdx2001 Rectal Carcinoma	ModeX Therapeutics, An OPKO Health Company	P1/2	CC (43)
Vsv-Gp128 Rectal Carcinoma	Amal Therapeutics	P1	CC (43)
Anakinra Rectal Carcinoma	Goethe University	P1	CC (42)
Epacadostat Rectal Carcinoma	Washington University School of Medicine	P1/2	CC (41)
Ropidoxuridine Rectal Carcinoma	National Cancer Institute (NCI)	P1	CC (41)
89zr-dfo-n-suc-c9scfv Rectal Carcinoma	Var2 Pharmaceuticals	Early P1	C (39)
89Zr-DFO-N-Suc-F8scFv Rectal Carcinoma	Var2 Pharmaceuticals	Early P1	C (39)
Bacillus Calmette-Guerin Live (Attenuated) Antigen Rectal Carcinoma	Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	P1	C (39)
Brodalumab Rectal Carcinoma	Brian Henick, MD	P1	C (39)
Copper Cu 64 Anti-Cea Monoclonal Antibody M5A Rectal Carcinoma	City of Hope Medical Center	Early P1	C (39)

Showing 51 to 100 of 111 assets

PreviousPage 2 of 3Next